Mirtazapine: A novel antidepressant combining clinical efficacy with improved tolerability

Primary Care Psychiatry

Volumn 3, Issue 1, 1997, Pages 7-16

  Kasper, S ^a  

^a UNIVERSITY OF VIENNA   (Austria)

Author keywords

Antidepressants; General practice; Major depression; Mirtazapine

Indexed keywords

ANTIDEPRESSANT AGENT; CLOMIPRAMINE; MIRTAZAPINE;

ARTICLE; DEPRESSION; DRUG EFFICACY; DRUG TOLERABILITY; HUMAN; MOOD; PRIORITY JOURNAL; SEDATION; SIDE EFFECT; WEIGHT GAIN;

EID: 0030973049     PISSN: 13552570     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (63)

1. Angst J (1992) How recurrent and predictable is depressive illness? In: Long-term Treatment of Depression (Eds SA Montgomery and F Rouillon), pp. 1-13. Wiley, Chichester.
2. Kessler RC, McGonagle KA, Zhao S, Nelson CB, Hughes M, Eshleman S, Witchen HU and Kendler KS (1994) Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Archives of General Psychiatry, 51, 8-19.
3. Weissman MM, Leaf PJ, Tischler GL, Blazer DG, Karno M, Bruce ML and Florio LP (1988) Affective disorders in five United States communities. Psychological Medicine, 18, 141-153.
4. Rorsman BA, Grasbeck A, Hagnell O, Lanke J, Ohman R, Ojesjo L and Otterbeck L (1990) A prospective study of first-incidence depression. The Lundby study 1957-1972. British Journal of Psychiatry, 156, 336-342.
5. Blacker CVR and Clare AW (1987) Depressive disorder in primary care. British Journal of Psychiatry, 150, 737-751.
6. Williams P and Skuse D (1988) Depressive thoughts in general practice attenders. Psychological Medicine, 18, 469-475.
7. Katon W and Schulberg H (1992) Epidemiology of depression in primary care. General Hospital Psychiatry, 14, 237-247.
8. Bridges K and Goldberg D (1987) Somatic presentation of depressive illness in primary care. In: The Presentation of Depression: Current Approaches (Eds P Freeling, LJ Downey and JC Malkin), pp. 9-11. Royal College of General Practitioners, London.
9. Paykel ES (1989) The background: extent and nature of the disorder. In: Depression: an Integrative Approach (Eds K Herbst K and ES Paykel), pp. 3-17. Heinemann, Oxford.
10. Rodin G, Craven J and Littleford C (1991) Depression in the Medically Ill: an Integrated Approach. Brunner/Mazel, New York.
11. MacDonald AJD (1986) Do general practioners 'miss' depression in elderly patients? British Medical Journal, 292, 1365-1307.
12. Freeling P, Rao BM, Paykel ES, Sireling LI and Burton RH (1985) Unrecognized depression in general practice. British Medical Journal, 290, 1880-1883.
13. Tyrer P, Seivewright N, Murphy S, Ferguson B, Kingdon D, Barczak P, Brothwell J, Darling C, Gregory S and Johnson AL (1988) The Nottingham study of neurotic disorder: comparison of drug and psychological treatments. Lancet, 2, 235-240.
14. Goldberg D, Steele JJ, Smith C and Spivey L (1980) Training family doctors to recognise psychiatric illness with increased accuracy. Lancet, 2, 521-523.
15. Whewell P, Gore V and Leach C (1988) Training general practioners to improve their recognition of emotional disturbances in the consultation. Journal of the Royal College of General Practice, 38, 259-262.
16. Blacker CVR and Clare AW (1988) The prevalence and treatment of depression in general practice. Psychopharmacology, 95, S14-S17.
17. Kasper S, Lepine JP, Mendlewicz J, Montgomery SA and Rush AJ Jr (1994/95) Efficacy, safety, and indications for tricyclic and newer antidepressants. Depression, 2, 127-137.
18. Edwards JG (1992) Selective serotonin re-uptake inhibitors: a modest though welcome advance in the treatment of depression. British Medical Journal, 304, 1644-1646.
19. de Boer T and Ruigt GSF (1995) The selective (2-adrenoceptor antagonist mirtazapine (Org 3770) enhances noradrenergic and 5-HT1A-mediated serotonergic neurotransmission. CNS Drugs, 4 (Suppl 1), 29-38.
20. Haddjeri N, Blier P and de Montigny C (1995) Noradrenergic modulation of central serotonergic neurotransmission: acute and long-term actions of mirtazapine. International Clinical Psychopharmacology, 10 (Suppl 4), 11-17.
21. de Boer T, Maura G, Raiteri M, de Vos CJ, Wieringa J and Pinder RM (1988) Neurochemical and autonomic pharmacological profiles of the 6-aza-analogue of mianserin, Org 3770 and its enantiomers. Neuropharmacology, 27, 399-408.
22. de Boer T, Nefkens F and Van Helvoirt A (1994) The (2-antagonist Org 3770 enhances serotonin transmission in vivo. European Journal of Pharmacology, 253, R5-R6.
23. Ruigt GSF, Kemp B, Groenhout CM and Kamphuisen HA (1990) Effect of the antidepressant Org 3770 on human sleep. European Journal of Clinical Pharmacology, 38, 551-554.
24. Montgomery SA (1995) Safety of mirtazapine: a review. International Clinical Psychopharmacology, 10 (Suppl 4), 37-45.
25. Timmer CJ, Lohmann AAM and Mink CPA (1995) Pharmacokinetic dose-proportionality study at steady state of mirtazapine from Remeron(tablets. Human Psychopharmacology, 10 (Suppl 2), S97-S106.
26. Voortman G and Paanakker JE (1995) Bioavailability of mirtazapine from Remeron tablets after single and multiple oral dosing. Human Psychopharmacology, 10 (Suppl 2), S83-S96.
27. Mattila M, Mattila MJ, Vrijmoed-de Vries M and Kuitunen T (1989) Action and interaction of psychotropic drugs on human performance and mood: single doses of Org 3770, amitriptyline and diazepam. Pharmacology and Toxicology, 65, 81-88.
28. Kasper S (1995) Clinical efficacy of mirtazapine: a review of meta-analyses of pooled data. International Clinical Psychopharmacology, 10 (Suppl 4), 25-35.
29. Bremner JD (1995) A double-blind comparison of Org 3770, amitriptyline, and placebo in major depression. Journal of Clinical Psychiatry, 56, 519-525.
30. Claghorn JL and Lesem MD (1995) A double-blind placebo-controlled study of Org 3770 in depressed outpatients. Journal of Affective Disorders, 34, 165-171.
31. Halikas JA (1995) Org 3770 (mirtazapine) versus trazodone: a placebo controlled trial in depressed elderly patients. Human Psychopharmacology, 10 (Suppl 2), S125-S133.
32. Khan MC (1995) A randomised, double-blind, placebo-controlled, 5-weeks' study of Org 3770 (mirtazapine) in major depression. Human Psychopharmacology, 10 (Suppl 2), S119-S124.
33. Smith WT, Glaudin V, Panagides J and Gilvary E (1990) Mirtazapine vs. amitriptyline vs. placebo in the treatment of major depression. Psychopharmacology Bulletin, 26, 191-196.
34. Vartiainen H and Leinonen E (1994) Double-blind study of mirtazapine and placebo in hospitalized patients with major depression. European Neuropsychopharmacology, 4, 145-150.
35. Sitsen JMA and Zivkov M (1995) Mirtazapine. Clinical profile. CNS Drugs, 4 (Suppl 1), 39-48.
36. Høyberg OJ, Maragakis B, Mullin J, Norum D, Stordall E, Ekdahl P, Ose E, Moksnes KM and Sennef C (1996) A double-blind multicentre comparison of mirtazapine and amitriptyline in elderly depressed patients. Acta Psychiatrica Scandinavica, 93, 184-190.
37. Mullin J, Lodge A, Bennie E, McCreadie R, Bhatt GS and Fenton G (1996) A multicentre, double-blind, amitriptyline-controlled study of mirtazapine in patients with depression. J Psychopharmacol, 10, 235-240
38. Zivkov M and de Jongh GD (1995) Org 3770 versus amitriptyline: a 6-week randomized double-blind trial in hospitalized depressed patients. Human Psychopharmacology, 10, 173-180.
39. Zivkov M, Roes KCB and Pols AG (1995) Efficacy of Org 3770 (mirtazapine) vs amitriptyline in patients with major depressive disorder: a meta-analysis. Human Psychopharmacology, 10 (Suppl 2), S135-S145.
40. Richou H, Ruimy P, Charbaut J, Deliste JP, Brunner H and Patris M (1995) A multicentre, double-blind, clomipramine-controlled efficacy and safety study of Org 3770. Human Psychopharmacology, 10, 263-271.
41. Mattila M, Jääskeläinen J, Järvi R, Romanov M, Miettinen E, Sorri P, Ahlfors U and Zivkov M (1995) A double-blind study comparing the efficacy and tolerability of mirtazapine and doxepin in patients with major depression. European Neuropsychopharmacology, 5, 441-446.
42. van Moffaert M, de Wilde J, Vereecken A, Dierick M, Evrard JL, Wilmotte J and Mendlewicz J (1995) Mirtazapine is more effective than trazodone: a double-blind controlled study in hospitalized patients with depression. International Clinical Psychopharmacology, 10, 3-9.
43. Kasper S, Zivkov M, Roes KGB et al. (1997) Pharmacological treatment of severely depressed patients: a meta-analysis comparing efficacy of mirtazapine and amitriptyline, European Neuropsychopharmacology, in press.
44. Akiskal H (1995) Mood disorders: clinical features. In: Comprehensive Textbook of Psychiatry, Vol. VI (Eds HI Kaplan and BJ Sadock), pp. 1123-1152. Williams and Wilkins, Baltimore.
45. Sitsen JMA and Moors J (1994) Mirtazapine, a novel antidepressant, in the treatment of anxiety symptoms. Results from a placebo-controlled trial. Dnig Investigation, 8, 339-344.
46. Bremner JD and Smith WT (1996) Org 3770 vs amitriptyline in the continuation treatment of depression: a placebo controlled trial. European Journal of Psychiatry, 10, 5-15.
47. Bech P, Allerup P, Reisby N and Gram LF (1984) Assessment of symptom change from improvement curves on the Hamilton depression scale in trials with antidepressants. Psychopharmacology, 84, 276-281.
48. Rudorfer MV, Manji HK and Potter WZ (1994) Comparative tolerability profiles of the newer versus older antidepressants. Drug Safety, 10, 18-46.
49. Fox T (1991) Drug treatment of anxiety and depression. Practitioner, 235, 681-683.
50. Henry JA, Alexander CA and Sener EK (1995) Relative mortality from overdose of antidepressants. British Medical Journal, 310, 221-224.
51. de Jonghe F and Swinkels JA (1992) The safety of antidepressants. Drugs, 43 (Suppl 2), 40-47.
52. Boyer WF and Blumhardt CL (1992) The safety profile of paroxetine. Journal of Clinical Psychiatry, 53, 61-66.
53. Doogan DP (1991) Toleration and safety of sertraline: experience worldwide. International Clinical Psychopharmacology, 6 (Suppl 2), 47-56.
54. Wernicke JF (1985) The side effect profile and safety of fluoxetine. Journal of Clinical Psychiatry, 46, 59-67.
55. Sternbach H (1991) The serotonin syndrome. American Journal of Psychiatry, 148, 705-713.
56. Preskorn SH (1993) Recent pharmacologic advances in antidepressant therapy for the elderly. American Journal of Medicine, 94 (Suppl 5), 2-12.
57. Mann JJ and Kapur S (1991) The emergence of suicidal ideation and behaviour during antidepressant pharmacotherapy. Archives of General Psychiatry, 48, 1027-1033.
58. Kasper S, Schindler S and Neumeister A (1996) Risk of suicide in depression and its implications for psychopharmacological treatment. International Clinical Psychopharmacology, 11, 71-79.
59. Rosenstein DL, Nelson JC and Jacobs SC (1993) Seizures associated with antidepressants: a review. Journal of Clinical Psychiatry, 54, 289-299.
60. Langsdale T (1995) WHO Collaborative Study on Psychological Problems in General Health Care: hidden burden of mental illness uncovered by World Health Organization study. Pharmacoresources, 26, 9.
61. Goldblatt MJ and Schatzberg AF (1991) Does treatment with antidepressant medication increase suicidal behavior? International Clinical Psychopharmacology, 6, 219-226.
62. Kind P and Sorensen J (1993) The costs of depression. International Clinical Psychopharmacology, 7, 191-195.
63. Scott AIF and Freeman CPL (1992) Edinburgh primary care depression study: treatment outcome, patient satisfaction, and cost after 16 weeks. British Medical Journal, 304, 883-887.